Abstract
Standardized therapeutic approaches to mycosis fungoides/Sézary syndrome have been demonstrated by a newly launched guideline for cutaneous lymphomas in Japan. However, we cannot treat all the patients, even at the same stage of the disease, with uniform regimens because of the differences in disease activities and progression. Since clinical responses to treatments may vary in each case, the choice and dosage of alternative regimens have been determined by doctors' own experiences. Nowadays, therapeutic options are limited because as compared with Western countries, only a few regimens have been approved officially in Japan. Therefore, we are obliged to select a feasible option among the limited regimens. In the present lecture, we show practical choices of treatments for each stage of mycosis fungoides and Sézary syndrome, and refer to a possible usage of molecular targeting agents.[Skin Cancer (Japan) 2010 ; 25 : 250-262]
